• Perineuronal Net Degradation in CA2 Drives Social Memory Los

  2026-06-04

  The reference study establishes that degradation of perineuronal nets (PNNs) in the hippocampal CA2 region is causally linked to social memory impairment in Alzheimer’s disease (AD) mouse models. It demonstrates that matrix metalloproteinase (MMP)-mediated PNN disruption is both necessary and sufficient for this cognitive deficit, and that chronic MMP inhibition preserves PNNs and delays social memory loss, highlighting new translational targets for AD intervention.

• Cefazedone (Refosporen): Applied Workflows & Troubleshooting

  2026-06-04

  Cefazedone (Refosporen) empowers robust, β-lactamase-resistant antibacterial workflows for both Gram-positive and Gram-negative pathogens. This article delivers protocol enhancements, troubleshooting strategies, and practical assay guidance, all anchored in the latest pharmacokinetic and analytical breakthroughs.

• AICAR in Energy Metabolism Regulation: Protocols and Pitfall

  2026-06-03

  AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) stands out for precise AMPK activation, empowering researchers to dissect energy metabolism and inflammation pathways in both cellular and animal models. This guide unpacks optimized workflows, troubleshooting strategies, and actionable insights based on breakthrough findings in muscle atrophy and metabolic disease research.

• GI 254023X: Precision ADAM10 Inhibitor for Cell Signaling Re

  2026-06-03

  GI 254023X stands out as a potent and selective ADAM10 inhibitor, enabling researchers to dissect cell adhesion, apoptosis, and endothelial barrier function in finely-tuned models. Its high specificity and robust solubility empower experimental workflows targeting Notch1 signaling and vascular protection. Discover how GI 254023X, supplied by APExBIO, delivers reproducible results in cutting-edge cell biology and translational studies.

• Tubastatin A Mitigates Myocardial Injury via Pyroptosis and

  2026-06-02

  A recent preclinical study demonstrates that Tubastatin A, a selective HDAC6 inhibitor, significantly reduces post-resuscitation myocardial injury in a porcine cardiac arrest model by inhibiting GSDME-mediated pyroptosis and MLKL-dependent necroptosis. These findings highlight a novel mechanistic avenue for myocardial protection and inform future translational and experimental research.

• Sorafenib (BAY-43-9006): Systems Biology and Host-Directed I

  2026-06-02

  Explore how Sorafenib (BAY-43-9006) advances cancer biology research and host-targeted antiviral strategies through dynamic transcriptomics. This article delivers a deeper, systems-level perspective on Sorafenib’s unique utility and mechanistic insights.

• (S)-Mephenytoin as a Benchmark CYP2C19 Substrate in Organoid

  2026-06-01

  (S)-Mephenytoin is redefining CYP2C19 substrate assays by enabling highly predictive, human-relevant drug metabolism workflows using hiPSC-derived intestinal organoids. This article delivers actionable protocol enhancements, troubleshooting guidance, and comparative analysis for translational pharmacokinetic studies leveraging APExBIO’s validated compound.

• Anti-ROR1 Antibody (Zilovertamab): Precision Tools for Model

  2026-06-01

  Explore how Anti-ROR1 Antibody (Zilovertamab) enables precision inhibition of Wnt5a-induced ROR1 signaling for advanced cancer and liver injury research. This article delivers new insights into experimental modeling, bridging mechanistic depth with practical protocol innovation.

• Bedaquiline: Precision Targeting in Tuberculosis and Oncolog

  2026-05-31

  Explore the unique diarylquinoline antibiotic Bedaquiline and its dual role in multi-drug resistant tuberculosis treatment and cancer stem cell inhibition. This article delivers a scientifically rigorous, application-focused analysis distinct from existing content.

• miR-18a/ALOXE3 Axis in Ferroptosis and Migration of Glioblas

  2026-05-30

  The reference study elucidates the tumor-promoting role of miR-18a in glioblastoma (GBM) through direct suppression of ALOXE3, affecting ferroptosis and cell migration. These findings reveal an actionable molecular axis with potential for targeted GBM research and interventions.

• SGC-CBP30: Precision Bromodomain Inhibition for Epigenetics

  2026-05-29

  SGC-CBP30 empowers advanced epigenetics and cancer biology research by selectively inhibiting CREBBP/EP300 bromodomains, enabling targeted dissection of super-enhancer regulation and transcriptional coactivator pathways. This article details practical workflows, troubleshooting strategies, and application-driven insights anchored in the latest lung adenocarcinoma research.

• Nonconventional Agonist–Antagonist Interplay at the GLP-1R

  2026-05-29

  Chepurny et al. (2019) reveal that glucagon acts as a nonconventional agonist at the GLP-1 receptor, challenging established views of receptor selectivity. High-throughput FRET cAMP assays demonstrate complex cross-reactivity between glucagon, GLP-1, and receptor antagonists, informing metabolic regulation and type 2 diabetes research.

• Tigecycline (SKU A5226): Data-Driven Solutions for Resistant

  2026-05-28

  This authoritative guide addresses real-world laboratory challenges in cell viability, proliferation, and cytotoxicity assays, focusing on Tigecycline (SKU A5226) as a robust, data-backed solution. Drawing on peer-reviewed research and practical workflow considerations, the article equips biomedical researchers and lab technicians with scenario-driven insights for optimizing experimental reproducibility and tackling multidrug-resistant bacteria.

• Neticonazole Hydrochloride: Imidazole Antifungal in Oncology

  2026-05-28

  Neticonazole Hydrochloride distinguishes itself as a dual-action imidazole antifungal with validated applications in both mycology and colorectal cancer research. This article delivers actionable protocols, troubleshooting strategies, and expert insights for leveraging Neticonazole Hydrochloride across experimental workflows, including exosome pathway modulation and apoptosis induction.

• QNZ (EVP4593): Advanced NF-κB Pathway Modulation in Research

  2026-05-27

  QNZ (EVP4593) is redefining NF-κB pathway modulation with nanomolar potency and proven translational value in both inflammation and neurodegenerative disease models. This article delivers actionable workflows, troubleshooting strategies, and insight into leveraging QNZ for robust, reproducible research outcomes.

455 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page